YORK, June 30, 2022 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) ("MindMed'' or the
"Company") announces that it has completed its previously announced
redesignation of its subordinate voting shares as common shares
(the "Common Shares") of the Company. The Common Shares will be
assigned CUSIP number 60255C802 and ISIN number CA60255C8025
following the redesignation. The Common Shares will begin trading
on a post-Redesignation basis under the new CUSIP and ISIN numbers
on the NEO Exchange and NASDAQ at market open on July 4, 2022 and July 5,
2022, respectively, under the existing trading symbols.
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, with a particular
focus on psychiatry, addiction, pain and neurology. Our mission is
to be the global leader in the development and delivery of
treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative drug
candidates, with and without acute perceptual effects, targeting
the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the NEO
Exchange under the symbol MMED.
For Media: firstname.lastname@example.org
For Investors: email@example.com
Cautionary Notes and Forward-looking
This news release includes certain statements that constitute
"forward-looking statements", and "forward-looking information"
within the meaning of applicable securities laws collectively
"forward-looking statements". These include statements regarding
the Company's intent, or the beliefs or current expectations of the
Company's officers and directors. When used in this new release,
words such as "will", "would", "subject to", "anticipates", "at
which time", "will allow", "pursue" and similar expressions are
intended to identify these forward-looking statements as well as
phrases or statements that certain actions, events or results
"may", "could", "would", "should", "occur" or "be achieved" or the
negative connotation of such terms. As well, forward-looking
statements may relate to the Company's future outlook and
anticipated events, such as the expectation that the Common Shares
will resume trading on July 4, 2022
on the NEO Exchange and July 5, 2022
on NASDAQ. Forward-looking statements are based on information
available at the time those statements are made and/or management's
good faith belief as of that time with respect to future events and
are subject to risks and uncertainties that could cause actual
performance or results to differ materially from those expressed in
or suggested by the forward-looking statements. Forward-looking
statements speak only as of the date those statements are made.
Except as required by applicable law, the Company assumes no
obligation to update or to publicly announce the results of any
change to any forward-looking statement contained or incorporated
by reference herein to reflect actual results, future events or
developments, changes in assumptions or changes in other factors
affecting the forward-looking statements. If the Company updates
any one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect to
those or other forward-looking statements. All forward-looking
statements contained in this news release are expressly qualified
in their entirety by this cautionary statement.
SOURCE Mind Medicine (MindMed) Inc.